An Observational Study for Gastric Cancer in Asymptomatic Carriers of High Risk Helicobacter Pylori
Launched by FUDAN UNIVERSITY · Mar 20, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the link between a specific type of bacteria called Helicobacter pylori (Hp) and the development of stomach cancer in people who do not have symptoms but carry a high-risk version of this bacteria. The researchers want to observe how often stomach cancer occurs and how any early signs of cancer progress in individuals with different types of Hp. The study aims to gather information from participants over time to better understand these risks.
To be eligible for this study, participants need to be at least 18 years old and must not have a history of stomach cancer. They should also be healthy enough to undergo testing, including breath tests or stomach biopsies, to check for Hp. Participants will not have any serious stomach problems or immediate medical needs. If someone joins the study, they can expect to have regular check-ups and tests to monitor their health. It's important to note that the study is not currently recruiting participants, so interested individuals will need to wait until it begins.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years old, gender is not limited;
- • 2. No previous history of gastric cancer (no radical surgery or radiotherapy treatment for gastric cancer);
- • 3. Able and willing to provide informed consent and willing to accept baseline and follow-up examinations;
- • 4. Able to cooperate in completing HP testing (breath test, gastroscopic biopsy or other standard testing methods) and HP SNP typing by stool testing;
- • 5. No obvious gastric symptoms at the time of initial screening, no progressive gastric cancer or serious gastric diseases (e.g., perforated acute ulcers, upper gastrointestinal hemorrhage, etc.) detected, and no need for urgent surgery (not planned within 3 months) or other therapeutic interventions for the time being.
- Exclusion Criteria:
- • 1. Diagnosed gastric cancer or other malignant tumors of the digestive tract;
- • 2. Comorbid serious underlying diseases (e.g., severe cardiopulmonary insufficiency, liver and renal failure, etc.) that are expected to have a short survival time or are not suitable for long-term follow-up;
- • 3. Inability to complete or refusal to undergo HP testing, SNP gene testing or follow-up;
- • 4. Presence of severe mental illness or incapacity for civil behavior that prevents completion of the study;
- • 5. Pregnant or breastfeeding women who are temporarily excluded;
- • 6. Other conditions that the investigator considers unsuitable for participation in this study.
About Fudan University
Fudan University, a prestigious comprehensive research university located in Shanghai, China, is committed to advancing medical science through innovative clinical research. Renowned for its rigorous academic standards and cutting-edge research facilities, Fudan University plays a pivotal role in the global health landscape by sponsoring a diverse array of clinical trials aimed at improving patient outcomes and addressing pressing medical challenges. Leveraging its multidisciplinary expertise and collaborative networks, the university strives to translate scientific discoveries into practical applications, fostering advancements in healthcare and contributing to the well-being of communities both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported